An mRNA treatment shrank lung tumors in mice and guarded against cancer muscle wasting

Lipid nanoparticles loaded with messenger RNA for the protein follistatin cut tumor burden in mouse lung cancer about 2.5-fold more than conventional nanoparticles did, and the same treatment protected the animals from the muscle and fat loss known as cachexia. The work comes from Oregon State University’s College of Pharmacy and was published in the Journal of Controlled Release (2026; volume 394, article 114870).

Oleh Taratula and Yoon Tae Goo led the team. Oregon State announced the result on April 6, 2026, and the October coverage recaps the paper. Taratula described the comparison in the university’s words: against conventional nanoparticles, which tend to accumulate in the liver after injection into the bloodstream, the approach achieved an approximately 2.5-fold greater reduction in tumor burden.

Follistatin mRNA riding on vitronectin

The nanoparticles carry follistatin messenger RNA, which instructs cells to make the follistatin protein, one the researchers say both inhibits tumors and promotes muscle growth. They are given intravenously. According to the Oregon State release, the particles bind vitronectin, a protein in blood, and that binding steers them toward integrin receptors that are overexpressed on the surface of tumors, which is how they reach the lung.

The liver is the standard destination for such particles, so redirecting them is the central design point, since the follistatin protein is credited with acting on both the tumor and the muscle. The 2.5-fold figure is relative: it compares tumor reduction with conventional liver-accumulating particles, and the summaries do not give absolute tumor sizes.

Messenger RNA is a delivery problem as much as a drug problem. The molecule is fragile and has to be packaged in a lipid shell to survive the blood, and a shell that lands in the liver does nothing for a tumor in the lung. The Oregon State approach, as the release describes it, relies on vitronectin in the bloodstream to steer the particles toward tumor integrins.

Cachexia in the mouse results

Cachexia is the severe loss of weight, fat and muscle that accompanies many cancers and continues even when a patient is eating. The ScienceDaily summary says it can kill as many as 30 percent of affected cancer patients. In the mice, the treatment improved food intake, maintained body weight and preserved muscle and fat tissue. Taratula said the therapy addresses lung cancer and cachexia all without adverse effects, a statement the summaries do not back with safety data.

The National Cancer Institute’s clinical summary defines cachexia as a multifactorial syndrome marked by ongoing loss of skeletal muscle mass and distinguishes it from simple starvation: raising calorie intake, by mouth or intravenously, has not reversed the wasting. The NCI page adds that tumor-related weight loss is common in lung, pancreatic and upper gastrointestinal cancers, that anorexia affects about 15 percent to 25 percent of patients at diagnosis, that sarcopenia, the loss of muscle, occurs in about 50 percent of patients with advanced cancer, and that malnutrition in general accounts for 10 percent to 20 percent of mortality in patients with cancer. That is why a single agent that acts on tumor and muscle together draws interest, since nutrition alone has not solved the second problem.

Lung cancer’s scale and what the mouse work omits

The American Cancer Society estimates 229,410 new lung cancer cases and about 124,990 deaths in the United States in 2026, and calls lung cancer by far the leading cause of cancer death, roughly 1 in 5 cancer deaths. Of the new cases, 110,910 are projected in men and 118,500 in women, and of the deaths, 63,040 in men and 61,950 in women.

Against that burden, the data in hand are thin, and every result described here, from the 2.5-fold tumor figure to the preserved muscle and fat, rests on animals alone, with the path from a mouse model to a first human dose still to be built. The Oregon State release refers only to a mouse model and does not give the cell line, strain, dosing, sample sizes, statistics or survival figures. An eCancer report repeats the same gaps. Taratula said more preclinical work is necessary but that the team is very encouraged and hopes testing in humans is down the road.

The team presents the work as preclinical and early, and the only human step it names is a hope for testing in people at some point in the future.

Funding came from the National Cancer Institute, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the National Research Foundation of Korea. Co-authors include Vladislav Grigoriev, Tetiana Korzun, Ammar Salem, Kongbrailatpam Shitaljit Sharma, Prem Singh, Chrissa Kioussi and Olena Taratula, plus Daniel Marks of Endevica Bio. Safety and effectiveness in patients are untested.

This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.

More from Morning Overview